UNSPSC 51343701: Tanomastat

This classification denotes a matrix metalloproteinase inhibitor with the molecular formula C23H19ClO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AM1ZX94EXH, chemically known as (s)-4-chloro-gamma-oxo-alpha-((phenylthio)methyl)(1,1-biphenyl)-4-butanoic acid but generally known as tanomastat, which bears US NIH Compound Identifier 177347. The term TANOMASTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44).

Most nations schedule Tanomastat under HS 29309085 and SITC 51549. As of Q4 2014, TANOMASTAT remains the US FDA Preferred Term for this commodity. Tanomastat bears US NLM identifiers UMLS ID C0393069 and NCI Concept Code C1705. SMILES: C1CCC(CC1)SC[C@@H](CC(=O)C2CCC(CC2)C3CCC(CC3)CL)C(=O)O.

UNSPSC 51343701 Tanomastat is a Commodity code that does not appear to reflect the actual work state and local governments are soliciting under this classification. The recent opportunities tagged to this code involve naloxone procurement, generic pharmaceuticals and OTC products through cooperative purchasing, direct-to-manufacturer pharmacy initiatives, and medical and first aid supplies for emergency response — none of which align with tanomastat, a specific pharmaceutical compound. The code shows little relevant recent activity for the product its name suggests.

Activity under this code, as currently tagged in state and local procurement systems, spans health and human services agencies, county health departments, and municipal fire-rescue divisions across Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems; the City of Tampa released an IFB (26P00145, due March 13, 2026) for medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000 and sheltered for certified Small Local Business Enterprises with a 5 percent bid discount; the Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products serving state and local facilities across Minnesota and Oregon. The mismatch between the code's nominal product and the actual procurements suggests either a tagging error in the source systems or that tanomastat is being procured under a broader pharmaceutical code. Firms pursuing work in emergency response medical supplies, public health pharmacy programs, or cooperative purchasing arrangements should verify code assignment with the issuing jurisdiction before investing in pursuit.